Europska Unija - hrvatski - EMA (European Medicines Agency)

linde healthcare ab - dušikov oksid - hypertension, pulmonary; respiratory insufficiency - drugi proizvodi respiratornog sustava - inomax, u kombinaciji s respiratornu podršku i drugih odgovarajućih aktivnih tvari, prikazan:za liječenje novorođenčadi ≥34 tjedna trudnoće s гипоксически respiratorni distres, povezane sa kliničkim ili эхокардиографических znakova plućne hipertenzije, s ciljem poboljšanja oksigenaciju i smanjenje potrebe za экстракорпоральной membranu oksigenaciju;u sklopu liječenja peri - i post-op plućne hipertenzije u odraslih i novorođenčad, dojenčad i malu djecu, djecu i mlade u dobi od 0-17 godina u kombinaciji s operacije na srcu, kako bi selektivno smanjenje plućne bolesti krvnog tlaka i poboljšanju funkcije desne klijetke i oksigenaciju.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sol s.p.a., via borgazzi 27, monza, italija - dušikov (ii) oksid - medicinski plin, stlačen - 1000 ppm mol/mol - urbroj: spremnik sadrži 1000 ppm mol/mol dušikovog(ii) oksida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sol s.p.a., via borgazzi 27, monza, italija - dušikov (ii) oksid - medicinski plin, stlačen - 225 ppm mol/mol - urbroj: spremnik sadrži 225 ppm mol/mol dušikovog(ii) oksida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sol s.p.a., via borgazzi 27, monza, italija - dušikov (ii) oksid - medicinski plin, stlačen - 450 ppm mol/mol - urbroj: spremnik sadrži 450 ppm mol/mol dušikovog(ii) oksida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

messer croatia plin d.o.o., industrijska 1, zaprešić - dušikov (ii) oksid - medicinski plin, stlačen - 800 ppm (v/v) - urbroj: spremnik za plin od 2 litre napunjen pri apsolutnom tlaku od 200 bara sadrži 381 litru plina pod tlakom od 1 bara pri 15 °c; spremnik za plin od 10 litara napunjen pri apsolutnom tlaku od 200 bara sadrži 1903 litre plina pod tlakom od 1 bara pri 15 °c; spremnik za plin od 20 litara napunjen pri apsolutnom tlaku od 200 bara sadrži 3806 litara plina pod tlakom od 1 bara pri 15 °c

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - tablete orkambi rezultati za liječenje муковисцидоза (mv) kod bolesnika u dobi od 6 i više godina, koji su гомозиготами na mutacije f508del u genu cftr . orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

jadran galenski laboratorij d.d., svilno 20, rijeka - venlafaxinum - kapsula s produljenim oslobađanjem, tvrda - 37,5 mg - urbroj: jedna kapsula s produljenim olsobađanjem sadrži 37,5 mg venlafaksina u obliku venlafaksinklorida